AbbVie weekly report: consolidates below MA-20 — sellers exhaust as long-term trend supports bulls

Traders Union
All News
Financial News
AbbVie rises 0.09% this week

Highlights

AbbVie secured a three-year voluntary agreement with the Trump administration to lower specific Medicaid drug prices, expand TrumpRx, and gain tariff exemptions and future price mandate relief.
The company committed $100 billion over the next decade for U.S. research, development, and capital expenditures, while signing a $650 million exclusive oncology licensing deal with RemeGen for RC148.
AbbVie expanded its pipeline in obesity and neuroscience and announced a 5.5% increase to its Q1 2026 dividend.

Policy relief and pipeline deals drive sentiment shifts over the week

AbbVie announced a three-year voluntary agreement with the Trump administration to reduce specific drug prices for Medicaid and expand its TrumpRx program, securing tariff exemptions and relief from future price mandates as part of the deal. The company committed $100 billion toward U.S. research, development, and capital expenditures over the coming decade. Additional developments include an exclusive licensing agreement with China's RemeGen for RC148 in oncology with a $650 million upfront payment, a pipeline expansion in obesity and neuroscience, and a 5.5% increase in its Q1 2026 dividend.

Bull tilt in technicals as short-term exhaustion meets long-term support

On the weekly chart, ABBV’s price sits below the MA-20, reflecting recent exhaustion in the short-term rally but remains firmly above both the MA-50 and MA-200, supporting the medium to long-term bullish structure. The Ichimoku Kijun at $214.72 provides immediate dynamic support, while resistance is clustered near $225. Weekly MACD readings are bullish, and the RSI on the W1 timeframe signals further upside potential, yet both Stoch RSI and CCI flag oversold conditions, suggesting selling pressure may be exhausted. Bull/Bear Power is still negative, confirming sellers’ dominance, while the Awesome Oscillator is neutral.

Range consolidation likely as bullish momentum eyes breakout risk

For the coming five to seven trading days, ABBV is expected to consolidate within the $215.85 to $225.12 range, maintaining moderate volatility. With over an 80% probability of an upward move, the baseline scenario anticipates range-bound trading, with bullish momentum potentially leading to a breakout above $225.12 and further gains. A break below $215.85 would put short-term pressure on the stock before longer-term support levels come into play.

Parshwa Turakhiya, analyst, views AbbVie’s weekly performance as a pause within a longer-term bullish framework. He notes persistent price strength above key moving averages, with medium- and long-term sentiment still constructive despite near-term exhaustion. The week’s news, especially the strategic U.S. deal and rich pipeline updates, supports confidence and investor appetite. With consolidation likely between $215.85 and $225.12, he believes a breakout is possible if momentum returns. "This week, I’m watching for bullish conviction to reignite — if buyers reclaim $225.12, it could set the tone for fresh upside."

Previously it was noted that AbbVie raised its quarterly dividend, reflecting solid business performance and continued shareholder returns. Several institutional investors adjusted their holdings in the recent quarter, while unusual trades involving the company were observed as investor repositioning intensifies as revenue outpaces.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.